Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY EVEROLIMUS VERSUS MYKOFENOLOVÁ KYSELINA U PACIENTŮ PO KOMBINOVANÁ TRANSPLANTACI LEDVINY A SLINIVKY BŘIŠNÍ ZA ÚČELEM ZHODNOCENÍ VÝVOJE NOVOTVORBY CÁV NA SÍTNICI U PACIENTŮ S DIABETICKOU RETINOPATIÍ

Trial Profile

EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY EVEROLIMUS VERSUS MYKOFENOLOVÁ KYSELINA U PACIENTŮ PO KOMBINOVANÁ TRANSPLANTACI LEDVINY A SLINIVKY BŘIŠNÍ ZA ÚČELEM ZHODNOCENÍ VÝVOJE NOVOTVORBY CÁV NA SÍTNICI U PACIENTŮ S DIABETICKOU RETINOPATIÍ

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 23 Sep 2022 Primary endpoint (Occurrence of blindness) has been met, according to Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
  • 23 Sep 2022 Primary endpoint (Worsening of visual acuity of more than 2 rows of Snellens optotypes) has been met, according to Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
  • 23 Sep 2022 Primary endpoint (Newly diagnosed clinically significant macular edema) has been met, according to Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top